EngageLab Upgrades Its Marketing Automation Functions with AI-Powered Features to Drive Customer Success
EngageLab Taking Marketing Automation to the Next Level
SINGAPORE, March 25, 2025 (GLOBE NEWSWIRE) -- EngageLab, already a leader in customer engagement, has upgraded its Marketing Automation (MA) functions with AI-powered capabilities, further empowering businesses to achieve exceptional results.
Revolutionizing Marketing with Key Features
Omnichannel Marketing Automation: Seamlessly connect with customers across AppPush, WebPush, Email, SMS, and WhatsApp to maximize engagement and conversions.Visual Journey Orchestration: A drag-and-drop builder with pre-designed templates enables marketers to create personalized user journeys without coding, reducing operational costs and increasing efficiency.AI-Driven Insights & Optimization: Real-time analytics track user behavior, participation rates, and revenue conversions, allowing businesses to optimize strategies for maximum ROI.Tailored Journey Orchestration for Diverse Scenarios
EngageLab's upgraded functions are designed to cater to various industries and use cases, including:
New User Onboarding: Guide users through core features for quick adoption.
Trial & Upgrade: Send reminders or exclusive offers to encourage payments.
Re-engagement: Reactivate inactive users with personalized incentives.
Targeted Campaigns: Leverage interaction data to deliver precise holiday deals or event teasers.Customer Success Stories
E-commerce: A B2C platform achieved a 30% increase in conversions and significantly higher repurchase rates using personalized campaigns.
Gaming: A mobile game developer boosted click-through rates by 45% and recovered 20% of churned players with behavior-triggered notifications.
Education: An online curriculum designer saw a 40% increase in course completions with tailored reminders via Push and SMS.
Why Choose EngageLab?
Powerful Messaging Channels: Five self-built messaging channels ensure high delivery rates and reliability.
AI-Powered Personalization: The integration of GPTBots.ai enables 24/7 personalized content creation and strategy optimization.
Global Support: A professional technical team provides 1-to-1 services and customized solutions for enterprises worldwide.
Ready to transform your marketing strategy? Experience the power of EngageLab's AI-driven Marketing Automation functions today from here: https://www.engagelab.com/accounts/signup
About EngageLab
EngageLab, a subsidiary of Aurora Mobile (NASDAQ: JG), is a leading multi-channel engagement solution provider, unites technology and versatility to offer seamless customer interactions and marketing automation across every channel, including Email, AppPush, WebPush, OTP, SMS, WhatsApp. It empowers businesses to build lasting relationships and achieve higher conversions and retention. With a strong focus on innovation and performance, EngageLab supports businesses with multiple global nodes, delivering more than 1 million messages every second across various channels.
For more information about EngageLab and its suite of solutions, visit www.engagelab.com.
For Media Inquiries:
Contact: marketing@engagelab.com | Website: www.engagelab.com
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/2f62b4ce-4b2d-4bc6-a741-bf9756c7647a
https://www.globenewswire.com/NewsRoom/AttachmentNg/759e72cd-56ae-49b4-8d32-96b264ee9f62
https://www.globenewswire.com/NewsRoom/AttachmentNg/a1a826ff-14f9-48ad-97e4-6b012456ac15
https://www.globenewswire.com/NewsRoom/AttachmentNg/53a5a7c6-6f15-4b48-8a42-658e123fc195Sign in to access your portfolio
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
Helius Medical Technologies, Inc. Compliant with Nasdaq Bid Price Rule Listing Criteria
Company previously granted extension until June 30, 2025 to regain compliance with Nasdaq's Equity Rule requirement NEWTOWN, Pa., June 04, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) ('Helius' or the 'Company'), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that on June 3, 2025, Helius received formal notice from the Nasdaq Hearings Panel of The Nasdaq Stock Market LLC (the 'Panel') indicating that Helius has evidenced full compliance with the minimum bid price requirement set forth Listing Rules 5550(a)(2) (the 'Bid Price Rule'). The Panel further reminded the Company that it is also required to regain compliance with the equity requirement in Listing Rule 5550(b)(1) (the 'Equity Rule') by June 30, 2025 under the extension previously granted by the Panel. Accordingly, the Nasdaq Listing Qualifications hearing process will remain open until the Company has demonstrated compliance with all of The Nasdaq Stock Market's continued listing requirements. About Helius Medical Technologies, Inc. Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using orally applied technology platform that amplifies the brain's ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The Company's first commercial product is the Portable Neuromodulation Stimulator (PoNS®). For more information about PoNS or Helius Medical Technologies, visit Cautionary Disclaimer Statement Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as 'believe,' 'expect,' 'continue,' 'will,' 'goal,' 'aim' and similar expressions. Such forward-looking statements include, among others, but are not limited to, statements regarding the Company's ability to achieve and maintain compliance with the Nasdaq listing rules. The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law. Investor Relations Contact Philip Trip TaylorGilmartin Groupinvestorrelations@
Yahoo
33 minutes ago
- Yahoo
BeautyHealth Surpasses 35,000 Hydrafacial Devices Worldwide Reflecting Growing Consumer Demand for Clinically Proven Skin Health Treatments
Underscores Hydrafacial's leadership and value to providers and consumers Hydrafacial Syndeo Device LONG BEACH, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- The BeautyHealth Company (NASDAQ: SKIN), home to flagship brand Hydrafacial™, recently achieved a major milestone with 35,000 Hydrafacial devices installed worldwide, reinforcing its market leadership in the hydradermabrasion category it pioneered. This accomplishment highlights the Hydrafacial treatment's continued global demand, fueled by strong brand awareness, and growing consumer preferences for non-invasive, results-driven skin health treatments. 'With providers delivering approximately 5 million Hydrafacial treatments last year1, our position as one of the most in-demand professional skin health treatments is clear,' said BeautyHealth Chief Executive Officer, Marla Beck. 'For nearly 28 years, Hydrafacial has been a treatment room essential powered by our science-based innovation and portfolio of 175+ patents that deliver the glowing results that clients and providers love. With a global footprint of 35,000 active Hydrafacial devices worldwide, we're empowering our community to meet rising demand for non-invasive aesthetic treatments and inspire skin confidence around the world.' Hydrafacial's success is backed by industry-leading consumer trust and satisfaction, ranking as the second most recognized facial treatment in the U.S.2 with a 96% 'Worth It' rating on RealSelf3, and an industry-leading 52 Net Promoter Score4. As a proven engine for practice growth, Hydrafacial treatments are responsible for driving approximately 7 percent of all new patients to medical spas and aesthetic practices each year.5 This enthusiasm for the brand translates to 1.5 Hydrafacial treatments performed every second around the world.6 The milestone reflects growing beauty trends favoring a natural, effortless look that prioritizes skin health – an aesthetic Hydrafacial treatments are uniquely designed to deliver. The Hydrafacial treatment combines seven powerful skin therapies in one: lymphatic drainage, a gentle peel, pain-free extractions, superficial microdermabrasion, a personalized booster, LED light therapy, and deep hydration. The result is visible skin improvements, a radiant glow, and a renewed boost in confidence – with zero downtime. 'We're grateful to the estheticians, dermatologists, and plastic surgeons who bring the iconic Hydrafacial glow to life every day,' Beck continues. 'Their trust and expertise drive our growth, and we remain committed to supporting them with ongoing innovation where MedTech Meets Beauty. Together, we're delivering real results – and a glow that keeps clients coming back.' To experience the Hydrafacial treatment and discover why consumers and providers alike trust Hydrafacial for radiant, healthy skin, find a provider near you by visiting and follow along on social @Hydrafacial. 1Company Data. 2Ipsos Study 2024. Base: Consumers of the aesthetic and professional beauty category (n=1000); Brand Aided Awareness. Conversion defined as % of respondents who are aware of and have tried a given brand.3RealSelf as of April 2025. 4Consumers of the aesthetic and professional beauty category that have received a Hydrafacial (n=210); 'On a scale of 0 to 10, how likely are you to recommend Hydrafacial to a friend or colleague?'5Guidepoint Qsight - Sales Measurement as of March 2025.6Treatments per second calculation based on 5 million treatments/year, spread across a 40-hour work week, 50 weeks in a year. About The Beauty Health CompanyThe Beauty Health Company (NASDAQ: SKIN) is a medtech meets beauty company delivering millions of skin health experiences every year that help consumers reinvent their relationship with their skin, bodies, and self-confidence. Our brands are pioneers: Hydrafacial™ in hydradermabrasion, SkinStylus™ in microneedling, and Keravive™ in scalp health. Together, with our powerful global community of estheticians, partners, and consumers, we are personalizing skin health for all ages, genders, skin tones, and skin types. We are committed to being ever more mindful in how we conduct our business to positively impact our communities and the planet. Find a local provider at and learn more at or LinkedIn. Forward-Looking StatementsCertain statements made in this release are 'forward looking statements' within the meaning of the 'safe harbor' provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words 'estimates,' 'projected,' 'expects,' 'anticipates,' 'forecasts,' 'plans,' 'intends,' 'believes,' 'seeks,' 'may,' 'will,' 'should,' 'future,' 'propose' and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements These forward-looking statements are not guarantees of future performance, conditions, or results, and involve a number of known and unknown risks, uncertainties, assumptions, and other important factors, many of which are outside The Beauty Health Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include The Beauty Health Company's ability to execute its business plan; consumers' perception of skin health, skin concerns, and overall beauty trends; the continued relationship amongst Hydrafacial, its providers, and consumers; the ability to place and continue to place delivery systems across various channels and locations; potential litigation involving The Beauty Health Company; changes in applicable laws or regulations; and the possibility that The Beauty Health Company may be adversely affected by other economic, business, and/or competitive factors. The Beauty Health Company does not undertake any obligation to update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except as required by Media Contact: Devries Global: jburchette@ Investors: IR@ Source: BeautyHealth A photo accompanying this announcement is available at
CNBC
33 minutes ago
- CNBC
An options strategy to maximize gains and minimize risk in this cloud AI winner
Oracle (ORCL) is undergoing a resurgence fueled by its leadership in artificial intelligence services and robust growth in Oracle Cloud Infrastructure (OCI). With OCI emerging as a preferred platform for AI workloads, Oracle has secured major partnerships like the $500 billion Stargate project with OpenAI and SoftBank, positioning it as a key player in the AI revolution. ORCL's attractive valuation, strong profitability and recent breakout signal suggests significant upside potential — making it a compelling candidate for bullish exposure in a market recovery. Trade timing The timing for adding bullish exposure to ORCL is optimal, as the stock recently broke above its $155 resistance and bounced higher as it retested it as support. This breakout is coupled with outperformance relative to the S & P 500 with an upside target of $190, offering an attractive risk-to-reward profile for a long position. Fundamentals ORCL trades at a meaningful discount to its industry despite superior profitability and growth metrics, positioning it as an undervalued tech name with significant upside potential. Forward PE ratio: 24.5x vs. industry average 27.7x Expected EPS growth: 13% vs. industry average 11% Expected revenue growth: 13% vs. industry average 9% Net margins: 21.8% vs. industry average 9.8% Bullish thesis AI-driven resurgence : Oracle's OCI revenue grew 49% YoY to $2.7 billion in Q3 FY2025, driven by demand for AI workloads signaling a strong pipeline for AI and cloud contracts. Strategic AI partnerships : Oracle's role in the $500 billion Stargate project with OpenAI and SoftBank, alongside deploying over 131,000 Nvidia Blackwell GPUs, cements its position as a key player in AI infrastructure. Attractive valuation : ORCL trades at 24x forward earnings, below the Nasdaq-100's 27.5x, with projected revenue growth of 13% in FY2026 and 18% in FY2027, highlighting significant upside potential. Technical breakout : The breakout above $155, with an upside target of $190, confirms strong momentum and potential for further gains as investor confidence grows. The trade To capitalize on ORCL's potential upside, I'm buying an Aug. 15 $170/$190 Call Vertical @ $7.12 Debit. This entails: Buying the Aug $170 Call @ $11.15 Selling the Aug $190 Call @ $4.03 The maximum reward is $1,288 if ORCL is above $190 at expiration. The maximum risk is $712 if ORCL is below $170 at expiration. The breakeven point for this trade is $177.12. View this trade with updated prices at OptionsPlay. This strategy positions you to benefit from ORCL's potential rally, leveraging its technical breakout, AI-driven growth and undervaluation to profit from a high-quality tech name with defined risk. With Oracle's leadership in AI-related cloud services, this call vertical offers a compelling opportunity to capture upside potential in a thriving industry. DISCLOSURES: None. All opinions expressed by the CNBC Pro contributors are solely their opinions and do not reflect the opinions of CNBC, NBC UNIVERSAL, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet or another medium. THE ABOVE CONTENT IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY . THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET. THE CONTENT IS GENERAL IN NATURE AND DOES NOT REFLECT ANY INDIVIDUAL'S UNIQUE PERSONAL CIRCUMSTANCES. THE ABOVE CONTENT MIGHT NOT BE SUITABLE FOR YOUR PARTICULAR CIRCUMSTANCES. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR. Click here for the full disclaimer.
